Company news
Protara Therapeutics, Inc. (NASDAQ:TARA) news
Protara Therapeutics, Inc. news releases on 6ix. Latest, Sep 8, 2026: Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment…
Press releases & updates
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
August 11, 2026
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
May 20, 2026
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
May 18, 2026
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
May 15, 2026
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
May 13, 2026
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
April 27, 2026
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
March 9, 2026
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
February 22, 2026
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 2, 2026
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
January 22, 2026
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
January 12, 2026
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support
January 7, 2026
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
January 5, 2026
Protara Announces Closing of $75 Million Public Offering
December 8, 2025
Protara Announces Proposed Public Offering
December 4, 2025
Protara Announces Pricing of $75 Million Public Offering
December 3, 2025
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
December 3, 2025
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025
December 1, 2025
Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
November 19, 2025
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
November 18, 2025
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology
November 17, 2025
Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
November 10, 2025
Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace
November 4, 2025
Protara Therapeutics to Participate in Upcoming Investor Conferences
August 27, 2025
Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
August 11, 2025
Protara Therapeutics Announces Addition to the Russell 3000® Index
June 30, 2025
Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer
June 2, 2025
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
May 8, 2025
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
April 26, 2025
Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025
April 23, 2025
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer
April 15, 2025
Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting
April 10, 2025
Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
March 19, 2025
Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
March 5, 2025
Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
February 26, 2025
Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 4, 2025
Protara Highlights Recent Updates and Anticipated 2025 Milestones
January 12, 2025
Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 7, 2025
Protara Announces Closing of $100 Million Public Offering
December 10, 2024
Protara Announces Pricing of $100 Million Public Offering
December 8, 2024
Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
December 4, 2024
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024
December 2, 2024
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
November 14, 2024
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
November 11, 2024
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
November 5, 2024
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
October 20, 2024
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
September 8, 2024
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
September 8, 2024